Revenue
2025
Neuphoria Therapeutics Inc. (NEUP)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $15.6M | — | — |
| Research & development | $9.0M | $9.4M | $13.1M |
| Operating expenses | $16.8M | $17.9M | $22.0M |
| Operating income | −$1.1M | −$17.9M | −$22.0M |
| EBITDAderived | −$466,201 | −$17.2M | −$21.3M |
| Net income | −$369,632 | −$15.5M | −$21.4M |
| Basic EPSper diluted share | -$0.23 | -$18.62 | -$0.02 |
| Diluted EPSper diluted share | -$0.23 | -$18.62 | -$0.02 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 21, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon stock, $0.00001 par value per share · indirect | 639.1K | $5.14 | $3.29M | 875.3K |